The GpHA and Biosimilars Council have published their objections to the Trans-Pacific Partnership trade agreement to the pages of the New York Times.
The FDA has approved Daklinza (daclatasvir), in combination with sofosbuvir, in treatment for chronic hepatitis C virus genotype 3 infections.
In a move that will reshape the generic pharmaceuticals landscape, Teva announced Monday that it would be acquiring Allergan Generics for $40.5 billion.
Anthem, Inc. will acquire all outstanding shares of Cigna Corporation in a transaction valued at $54.2 billion.
The National Association of Chain Drug Stores today announced that the Exhibit Hall for the 2015 NACDS Total Store Expo, which will take place from Aug. 22 to 25 at the Colorado Convention Center in Denver, is sold out.
The Food and Drug Administration announced Friday that it had approved Novartis’ Odomzo (sonidegib). The drug is meant to treat basal cell carcinoma, the most common form of advanced skin cancer.
The Food and Drug Administration announced Friday that it approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis.
On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.
Diplomat Pharmacy has partnered with Pharmaca Integrative Pharmacy to offer Pharmaca patients access to specialty pharmacy services.
Lupin announced Thursday that it will acquire Gavis Pharmaceuticals and Novel Laboratories in a $880 million, cash- and debt-free transaction.